Lynx Investment Advisory Vaxcyte, Inc. Call Options Transaction History
Lynx Investment Advisory
- $139 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCVX
# of Institutions
299Shares Held
110MCall Options Held
246KPut Options Held
118K-
Black Rock Inc. New York, NY9.94MShares$1.06 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.05 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$946 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$875 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$490 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.33B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...